Mizuho has downgraded STAAR Surgical (NASDAQ:STAA ... The investment bank said the "sharpness of the correction" of China ICL ...

In other recent news, STAAR Surgical Company reported a 10% year ... by a 10% rise in sales of its Implantable Collamer Lens (ICL (TASE:ICL)) products. Despite macroeconomic challenges ...

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the following ...

Shares of Staar Surgical Co. dropped 25% on Feb. 11 after it surprised ... “As an ophthalmologist, I have seen first-hand the life-changing impact that EVO ICL can have on patients,” Yeu said in a ...

Staar Surgical STAA has been analyzed by 5 analysts ... The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive ...

Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including STAAR Surgical (NASDAQ:STAA) and its peers.

Staar Surgical (NASDAQ:STAA) announced the following leadership shakeup: Warren Foust has been promoted to the newly created role of President and Chief Operating Officer. Magda Michna has been ...

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the following ...